4519.T
$8650.00-336.00 (-3.74%)
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Recent News
Roche stops work on experimental SMA drug
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy Launch - And What's Next
In late February 2026, Sarepta Therapeutics reported fourth‑quarter 2025 revenue of US$442.93 million and a net loss of US$412.23 million, while CEO Douglas Ingram notified the company of his plan to retire by the end of 2026 or upon appointment of a successor. At the same time, Sarepta and partner Chugai launched ELEVIDYS, Japan’s first gene therapy for Duchenne muscular dystrophy, underscoring the company’s ongoing commercial pivot amid leadership transition and recent safety‑related...
Assessing Chugai Pharmaceutical (TSE:4519) Valuation Following Strong Share Price Gains
Chugai Pharmaceutical (TSE:4519) has delivered a steady annual revenue growth of nearly 5% and net income growth close to 9% recently. Investors keep a keen eye on these metrics as the healthcare landscape in Japan continues to evolve. See our latest analysis for Chugai Pharmaceutical. Chugai Pharmaceutical’s share price has shown impressive momentum this year, recently jumping 8.25% over the past week and adding 20.24% in the last three months. The company’s performance has translated into a...
Chugai acquires Renalys, enhancing its kidney disease portfolio
Chugai will secure exclusive rights to develop and market Renalys’ sparsentan in South Korea, Japan and Taiwan.
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value drivers: the platform technology RaniPill, a recent […]